KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oscar Health (OSCR) Shares Outstanding (Diluted Average) (2020 - 2025)

Oscar Health (OSCR) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $262.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) fell 1.3% year-over-year to $262.4 million, compared with a TTM value of $262.4 million through Dec 2025, down 1.3%, and an annual FY2025 reading of $262.4 million, down 1.3% over the prior year.
  • Shares Outstanding (Diluted Average) was $262.4 million for Q4 2025 at Oscar Health, up from $255.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $305.9 million in Q1 2025 and bottomed at $88.9 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $227.6 million, with a median of $219.6 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) surged 511.57% in 2021, then decreased 15.93% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $179.0 million in 2021, then rose by 18.72% to $212.5 million in 2022, then increased by 4.32% to $221.7 million in 2023, then grew by 19.94% to $265.9 million in 2024, then fell by 1.3% to $262.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for OSCR at $262.4 million in Q4 2025, $255.4 million in Q3 2025, and $255.5 million in Q2 2025.